Details of the Drug Combination

General Information of Drug Combination (ID: DC2DT5Z)

Drug Combination Name
Rufinamide Moricizine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Rufinamide   DMWE60C Moricizine   DMOMBJW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 16.07
Bliss Independence Score: 16.07
Loewe Additivity Score: 31.25
LHighest Single Agent (HSA) Score: 31.25

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rufinamide
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved (orphan drug) [2]
Pediatric lennox-gastaut syndrome 8A62.1 Approved [3]
Seizure disorder 8A6Z Approved [2]
Rufinamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Blocker [7]
------------------------------------------------------------------------------------
Rufinamide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Carboxylesterase 1 (CES1) DEB30C5 EST1_HUMAN Metabolism [8]
Carboxylesterase 2 (CES2) DETHCPD EST2_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Indication(s) of Moricizine
Disease Entry ICD 11 Status REF
Arrhythmia BC9Z Approved [4]
Long QT syndrome BC65.0 Approved [5]
Heart arrhythmia BC65 Withdrawn from market [6]
Moricizine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Voltage-gated sodium channel alpha Nav1.5 (SCN5A) TTZOVE0 SCN5A_HUMAN Blocker [9]
------------------------------------------------------------------------------------
Moricizine Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [10]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7470).
3 Clinical pipeline report, company report or official report of Eisai.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Moricizine FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7244).
7 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
8 Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
9 From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
10 Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos. 2008 Jun;36(6):1046-55.